Key Takeaways
- Strong quarter, volume-led: Revenue grew 31% YoY to ₹229 crores, with both turnover and volume up 31%, indicating stable pricing and pure demand-driven growth.
- Shalvis is now live: Commercial production of technical products has commenced, and the facility is expected to contribute ₹80–100 crores in FY27, marking the start of a multi-year capacity build-out.
- Profitability improved with scale: EBITDA margin expanded to 18% from 17% YoY, and net profit rose 41% YoY, as operating leverage and cost efficiencies kicked in.
- Export mix is seasonal, not broken: Export revenue fell sequentially from ₹140 crores to ₹96 crores, but management attributed this entirely to seasonal phasing: EU products sell more in Q2, Australia products in Q3.
- What to watch next quarter: Whether the Japanese CDMO client visit in early March converts into a materialized deal, and whether the Board-approved capex plan for Shalvis and Sandila lands within the ₹105–130 crores guided range.
Shalvis Facility: The Growth Engine
- Commercial production started: Technical product manufacturing has commenced at the new Shalvis facility, with the first block now operational.
- FY27 revenue contribution: Two blocks are expected to generate ₹80–100 crores in the next financial year, with the second block ready by August/September 2026.
- Long-term build-out plan: Management intends to add 2–3 blocks every year for the next 3–4 years, accommodating around 10 blocks total, and targeting approximately ₹1,000 crores in revenue from Shalvis at the end of 5 years.
- Product pipeline for new blocks: Fungicide, herbicide, and specialty products are lined up for the upcoming blocks.
- Government incentive: The facility will qualify for a government incentive calculated as a percentage of plant and machinery spend, spread over 10 years after completion of the first phase; accrual begins once production starts next year.
D.K. Jain: "We will be putting up 2 to 3 blocks every year for the coming 3 to 4 years. We can accommodate around 10 blocks there easily. And what we feel that at the end of 5 years, we should be able to achieve a revenue of about INR1,000 crores."
CDMO Pipeline & New Registrations
- Active CDMO discussions: Projects are underway with customers from Japan, USA, and Australia. A Japanese client is visiting in the first week of March, and management is "quite hopeful" of materialization. Samples have been sent and approved for two other clients.
- Registration wins: The company received 5 registrations from CIB and 6 overseas (formulations and technical combined) last quarter, including a formulation registration for a fungicide in Australia and additional registrations in Europe and New Zealand.
- Revenue from new registrations: The Australia and New Zealand registrations are expected to generate at least ₹10–15 crores.
- Future registration pipeline: Management is working on approximately 5 reports and expects at least 7–8 registrations abroad next year, with a similar number pending with CIB.
- Fungicide technical product: One fungicide technical product is progressing well and is expected to contribute approximately ₹50 crores in revenue.
D.K. Jain: "With our Japanese friend, they will be visiting us in the first week of March again. And we are quite hopeful that it will get materialized."
Financial Performance & Mix
- Revenue and profit growth: 9M FY26 revenue reached ₹808 crores, up 28% YoY, while 9M net profit rose 44% YoY to ₹89 crores.
- EBITDA margin walk: Q3 EBITDA of ₹41 crores (up 39.7% YoY) delivered an 18% margin, a 100 bps improvement driven by better operating leverage and ongoing cost efficiencies.
- Revenue composition: Technical and API contributed 73% of Q3 revenue, formulations 27%; exports were 42%, domestic 58%.
- Export demand drivers: Export sales rose 28% YoY, supported by good demand in Europe and Australia; domestic sales increased 33% YoY on higher demand for herbicides and their intermediates.
- Other expenses explained: The increase in other expenses was volume-driven (power, contract labor, job work charges correlate directly with production), with only a ₹0.6 crores one-off from wage code implementation in employee benefit expenses.
- Tax rate clarification: The higher tax rate of 30–33% in the last two quarters includes deferred tax and prior-year tax; the actual ongoing rate is approximately 25%.
Capacity, Capex & Backward Integration
- Current utilization: 9M FY26 capacity utilization was around 65%; the existing PEDA/Pretilachlor plant was running above 80% before its expansion.
- Pretilachlor PEDA expansion: The expanded-capacity plant has been commissioned, strengthening backward integration.
- FY27 capex plan: Approximately ₹80–100 crores for Shalvis and ₹25–30 crores for the Sandila unit, totaling ₹105–130 crores, to be funded mostly through internal accruals.
- Sandila expansion: Plans include one technical plant and expansion in bulk formulation activity; the exact component will be worked out by next month, with Board approval targeted by March.
- Total capacity target: The company will achieve approximately 29,000 metric tons of capacity, with the majority of 30,000 tons expected to be utilized next year.
- Solar power: A 6-megawatt solar power supply from a group captive solar plant has begun at the Sandila unit, supporting cost competitiveness.
D.K. Jain: "Our objective is not short-term pricing advantage, but long-term cost competitiveness against global manufacturers."
Long-Term Roadmap & Investor Engagement
- ₹3,000 crores vision by March 2031: The breakup: Hamirpur (Shalvis) ₹1,000–1,100 crores, existing technical business approximately ₹1,500 crores, and B2C approximately ₹500 crores.
- Near-term growth target: With Shalvis and the existing IPL business combined, management is targeting a 20–25% increase in turnover.
- Margin outlook: Management aims to keep margins in the 18–20% range, consistent with current levels.
- Investor visibility acknowledged: When asked why strong performance is not reflecting in market capitalization, management initially deflected, then committed to making more efforts: contacting IR for more investor meetings and working on getting research reports published.
D.K. Jain: "We will make some more efforts on this, sir. We will contact our IR, and we will ask them to have more investor meetings. And as you rightly said that maybe some research reports could be published, we will have an internal meeting, and we will certainly work on this."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Shalvis revenue contribution | ₹80–100 crores from first two blocks | FY27 |
| Shalvis second block | Ready for production | August/September 2026 |
| Shalvis long-term revenue | Approximately ₹1,000 crores | End of 5 years |
| Total company revenue target | ₹3,000 crores (Hamirpur ~₹1,000–1,100 cr, existing technical ~₹1,500 cr, B2C ~₹500 cr) | By March 2031 |
| FY27 revenue growth | Approximately 20% over FY26 | FY27 |
| FY27 capex | ₹80–100 crores (Shalvis) + ₹25–30 crores (Sandila) | FY27 |
| Sandila capex plan finalization | Exact component to be worked out and Board approval sought | By March 2026 |
| New registration revenue | At least ₹10–15 crores from Australia and New Zealand registrations | Not specified |
| Future registrations | At least 7–8 registrations abroad | Next year |
| Fungicide technical product | Approximately ₹50 crores revenue contribution | Not specified |
| EBITDA margin range | 18% to 20% | Ongoing |
| Government incentive at Shalvis | Percentage of plant and machinery, spread over 10 years | Accrues after first phase completion |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Total revenue | ₹229 cr, +31% YoY |
| EBITDA | ₹41 cr, +39.7% YoY |
| EBITDA margin | 18%, up from 17% in Q3 FY25 |
| Net profit | ₹23 cr, +41% YoY |
| PAT margin | 10% |
| 9M FY26 total revenue | ₹808 cr, +28% YoY |
| 9M FY26 net profit | ₹89 cr, +44% YoY |
| Export revenue | ₹96 cr, +28% YoY; 42% of total revenue |
| Domestic revenue | ₹130 cr, 58% of total revenue |
| Technical and API share of revenue mix | 73%, formulations 27% |
| Capacity utilization | 65% for Q3 |
| PEDA and Pretilachlor combined revenue | ₹50 cr to ₹60 cr in Q3 |
| B2C share of total turnover | 18% to 20% |
| FY27 revenue growth guidance | ~20% over FY26 |
| FY27 EBITDA margin guidance | 18% to 20% |